+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Aneurysmal Subarachnoid Hemorrhage (aSAH)- Market Insight, Epidemiology and Market Forecast -2030

  • ID: 4564658
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 200 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Arbor Pharmaceuticals
  • BIT Pharma
  • Evgen Pharma
  • Grace Therapeutics
  • Idorsia Pharmaceuticals
  • MORE
‘Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (aSAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Aneurysmal Subarachnoid Hemorrhage (aSAH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market size from 2017 to 2030. The report also covers current Aneurysmal Subarachnoid Hemorrhage (aSAH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Aneurysmal Subarachnoid Hemorrhage (aSAH) Disease Understanding and Treatment Algorithm

Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview

Spontaneous (nontraumatic) subarachnoid hemorrhage (SAH) usually results from the rupture of a cerebral aneurysm. These aneurysms, which are located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of a ruptured aneurysm or polycystic kidney disease). Aneurysmal SAH is a worldwide health burden with high fatality and permanent disability rates. It is defined, according to the standard criteria, as an abrupt onset of a severe headache and/or loss of consciousness, with or without focal neurological signs, with CT, necropsy, or lumbar puncture, evidence of focal or generalized blood in the subarachnoid space.

The subarachnoid space is the area between the brain and the skull. It is filled with cerebrospinal fluid (CSF), which acts as a floating cushion to protect the brain. When blood is released into the subarachnoid space, it irritates the lining of the brain, increases pressure on the brain, and damages brain cells subsequently. At the same time, the area of the brain that received oxygen-rich blood from the affected artery previously is now deprived of blood, resulting in a stroke. Besides, SAH is frequently a sign of a ruptured aneurysm. Clotted blood and fluid buildup, enclosed within the rigid skull, increase the pressure that can crush the brain against the bone or cause it to shift and herniate. Moreover, blockage of the normal CSF circulation can enlarge the ventricles (hydrocephalus), causing confusion, lethargy, and loss of consciousness.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Diagnosis

The diagnosis of Aneurysmal Subarachnoid Hemorrhage (aSAH) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests such as computerized tomography, lumbar pucture, and magnetic resonance imaging (MRI).

Subarachnoid hemorrhage (SAH) is a characterized by bleeding into the subarachnoid space around the brain and spinal cord, as shown in the images below; generally, the subarachnoid space is filled with clear, colorless cerebrospinal fluid (CSF). The most common causes of subarachnoid hemorrhage are head trauma and rupture of an intracranial aneurysm. As radiologic evaluation is essential for determining the prognosis and treatment of subarachnoid hemorrhage, radiologic interventional procedures have become increasingly crucial for the management of this condition.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Treatment

Once in the critical care setting, the main goals of treatment are the prevention of rebleeding, the prevention and management of vasospasm, and the treatment of other medical and neurologic complications. Blood pressure should be maintained within the normal limits, and if necessary, intravenous antihypertensive agents such as labetalol and nicardipine can be used. Once the aneurysm is secured, hypertension is allowed, but there is no agreement on the range. Analgesia is often required, and reversible agents such as narcotics are indicated. Calcium antagonists reduce the risk of poor outcome from ischemic complications, and oral nimodipine is currently recommended. Prolonged administration of antifibrinolytic agents reduces rebleeding but is associated with an increased risk of cerebral ischemia and systemic thrombotic events. Although early treatment of aneurysms has become the mainstay of rebleeding prevention, antifibrinolytic therapy may be used in the short term before aneurysm treatment.

Further, nimodipine is the only pharmacological intervention shown to improve outcome in SAH patients, although it has no impact on large-vessel vasospasm. The commonly used pain-relieving medications include morphine and a combination of codeine and paracetamol. The other medications that may be used to treat a subarachnoid hemorrhage include anticonvulsants, such as phenytoin - which may be used to prevent seizures (fits), and antiemetics, such as promethazine - which can help stop you feeling sick and vomiting. Currently, the two main therapeutic options for securing a ruptured aneurysm are microvascular neurosurgical clipping and endovascular coiling. Historically, microsurgical clipping has been the preferred method of treatment. Also, endovascular treatment of aneurysms has been available as an alternative to surgical therapy for the past 15 years.

It covers the details of conventional and current medical therapies available in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market for the treatment of the various types of Aneurysmal Subarachnoid Hemorrhage (aSAH). It also provides the treatment guidelines and algorithms of the United States and Europe. The Aneurysmal Subarachnoid Hemorrhage (aSAH) market report gives a thorough understanding of Aneurysmal Subarachnoid Hemorrhage (aSAH) by including details such as disease definition, comorbidities, causes, risk factors, pathogenesis, and diagnosis.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH), Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), and Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) scenario of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030. The additional segments include Gender-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) and Hunt-Hess Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH).

Key Findings

This section provides glimpses of the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology in the 7MM.
  • In the 7MM, the total incident of Subarachnoid Hemorrhage (SAH) was estimated to be 63,072 cases in 2017 whereas the total incident of Aneurysmal Subarachnoid Hemorrhage (aSAH) was estimated to be 53,611.
  • According to the analysis, the estimated cases in WFNS grade-wise segmentation in 2017 for I-II, III, IV-V was 1,740, 305, and 1,196 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 1,393, 244 and 957 in Germany.
  • Several manifestations act as a contributor in course of development of aSAH. A total of 9,193, 3,940, 9,718, 10,112, 6,960 and 4,597 cases develop during aSAH i.e., Angiographic Vasospasm, Delayed ischemic neurologic deficit (DIND), Headache, Nausea or Vomiting, Loss of Conciousness and Nuchal Rigidity in 2017, which as per assessments will decrease to 8,391, 3,596, 8,870, 9,230, 6,353 and 4,195 cases, respectively, in 2030 in the US.
  • According to the analysis, the estimated cases in Fisher grade-wise segmentation in 2017 for I-II, III-IV is 468, and 1,930 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 374 and 1,545 (France).
Country Wise-Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology

The epidemiology segment also provides the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Drug Chapters

The drug chapter segment of the Aneurysmal Subarachnoid Hemorrhage (aSAH) report encloses the detailed analysis of Aneurysmal Subarachnoid Hemorrhage (aSAH) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Aneurysmal Subarachnoid Hemorrhage (aSAH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Marketed Drugs

Nymalize (nimodipine): Arbor Pharmaceuticals

Nymalize (Nimodipine) is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. Nymalize is the only oral nimodipine solution approved by the US FDA. In September 2011, Orphan Product Development (OOPD) granted Nymalize, an oral nimodipine solution, orphan drug designation for the treatment of subarachnoid hemorrhage. In October 2015, orphan designation (EU/3/15/1554) was granted by the European Commission to for nimodipine for the treatment of aSAH.

Products detail in the report.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Drugs

SFX-01: Evgen Pharma

SFX-01 is a synthetic form of sulforaphane stabilized by a -cyclodextrin ring and is the codename for the first product to use the Sulforadex technology. The drug is known to modulate key signaling pathways involved in cellular protection and inflammation. It is under development by Evgen Pharma and is being developed using Evgen's proprietary Technology, Sulforadex, which creates new and stable variants of sulforaphane, enabling it to be used as a first-time therapeutic. The US FDA has also granted Orphan drug designation for the use of stabilized sulforaphane in subarachnoid hemorrhage.

Clazosentan: Idorsia Pharmaceuticals

Clazosentan is an endothelin receptor antagonist in development as an intravenous infusion for cerebral vasospasm secondary to aSAH. Idorsia believes clazosentan can decrease the need for invasive intervention (i.e., angioplasty), which is currently used in such conditions at a high cost and with high medical risks. Currently, clazosentan has completed a Phase II study, REVERSE - which evaluated whether clazosentan has a rapid effect in reversing angiographically - confirmed cerebral vasospasm in patients with aSAH treated by endovascular coiling or surgical clipping. Clazosentan was granted orphan status in Europe in 2003 and the US in 2006.

GTX-104: Grace Therapeutics

GTX-104 is the injectable drug, designed to help people with SAH caused by a ruptured brain aneurysm, SAH is a rare and life-threatening medical emergency in which bleeding occurs in the subarachnoid space between the brain and the skull. This drug is under development by Grace Therapeutics which is in phase III pivotal study for the patients of SAH.

EG-1962: Edge Therapeutics/PDS Biotechnology Corporation

EG-1962 is a polymer-based microparticle containing nimodipine and calcium channel antagonists under development by Edge Therapeutics for the treatment of aSAH patients. A single dose of EG-1962 delivers high concentrations of nimodipine, the current standard of care, directly to the brain with sustained drug exposure over 21 days. EG-1962 utilizes Edge's proprietary, programmable, biodegradable polymer-based development platform, known as Precisa. In May 2016, Edge Therapeutics announced that the US FDA has granted Fast Track designation to its investigational product EG-1962 for the treatment of subarachnoid hemorrhage (SAH).

Products detail in the report.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook

Currently, the treatment comprises of Nymalize, which is the only approved drug and mainstay of treatment for the patients with aSAH. Nymalize (Nimodipine) is the calcium channel antagonist with a powerful antihypertensive activity and a unique cerebrovascular profile. The commonly used pain-relieving medications include morphine and a combination of codeine and paracetamol. The other medications that may be used to treat a subarachnoid hemorrhage include anticonvulsants, such as phenytoin - which may be used to prevent seizures (fits), and antiemetics, such as promethazine - which can help stop you feeling sick and vomiting. Currently, the two main therapeutic options for securing a ruptured aneurysm are microvascular neurosurgical clipping and endovascular coiling.

The Aneurysmal Subarachnoid Hemorrhage (aSAH) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Aneurysmal Subarachnoid Hemorrhage (aSAH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Aneurysmal Subarachnoid Hemorrhage (aSAH) 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Aneurysmal Subarachnoid Hemorrhage (aSAH) 7MM market.
  • According to the publisher estimates, the United States accounts for the largest market size of Aneurysmal Subarachnoid Hemorrhage (aSAH), in comparison to Japan and EU5 (the United Kingdom, Germany, Italy, France, and Spain).
  • The market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the seven major markets is USD 155.47 Million in 2017.
  • Among 7MM, Japan accounts for the second highest market size during the forecast period 2017-2030, at a CAGR of 9.44% for the study period (2017-2030).
The United States Market Outlook

This section provides the total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in Japan are provided.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Aneurysmal Subarachnoid Hemorrhage (aSAH) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Aneurysmal Subarachnoid Hemorrhage (aSAH) emerging therapies.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Aneurysmal Subarachnoid Hemorrhage (aSAH) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Aneurysmal Subarachnoid Hemorrhage (aSAH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Aneurysmal Subarachnoid Hemorrhage (aSAH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
Report Highlights
  • In the coming years, Aneurysmal Subarachnoid Hemorrhage (aSAH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Aneurysmal Subarachnoid Hemorrhage (aSAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH). Launch of emerging therapies will significantly impact the Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) Pipeline Analysis
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Key Strengths
  • Eleven Years Forecast
  • 7MM Coverage
- Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the Aneurysmal Subarachnoid Hemorrhage (aSAH) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Aneurysmal Subarachnoid Hemorrhage (aSAH) market size during the forecast period (2020-2030)?
  • At what CAGR, the Aneurysmal Subarachnoid Hemorrhage (aSAH) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What is the historical Aneurysmal Subarachnoid Hemorrhage (aSAH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Aneurysmal Subarachnoid Hemorrhage (aSAH) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to asperillosis?
  • Out of the above-mentioned countries, which country would have the highest incident population of Aneurysmal Subarachnoid Hemorrhage (aSAH) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the US and Europe?
  • What are the Aneurysmal Subarachnoid Hemorrhage (aSAH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • How many therapies are developed by each company for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aneurysmal Subarachnoid Hemorrhage (aSAH) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Aneurysmal Subarachnoid Hemorrhage (aSAH) and their status?
  • What are the key designations that have been granted for the emerging therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What are the 7MM historical and forecasted market of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Aneurysmal Subarachnoid Hemorrhage (aSAH).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Aneurysmal Subarachnoid Hemorrhage (aSAH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
  • To understand the future market competition in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Arbor Pharmaceuticals
  • BIT Pharma
  • Evgen Pharma
  • Grace Therapeutics
  • Idorsia Pharmaceuticals
  • MORE
1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Overview at a Glance
4.1 Market Share (%) Distribution of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2017
4.2 Market Share (%) Distribution of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2030

5 Disease Background and Overview: Aneurysmal Subarachnoid Hemorrhage
5.1 Introduction
5.2 Risk Factors
5.3 Clinical Presentation
5.3.1 Cardiac Manifestations
5.3.2 Neurogenic Pulmonary Edema (NPE)
5.3.3 Hypertension
5.4 Grading
5.4.1 World Federation of Neurosurgeons SAH Scale (WFNS)
5.4.2 The Hunt and Hess Scale
5.4.3 Fisher Scale
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Computerized tomography (CT scan)
5.6.2 Lumbar puncture
5.6.3 Magnetic resonance imaging (MRI)
5.6.4 Aneurysm detection
5.7 Management
5.7.1 Acute Management
5.7.2 Management of the ruptured aneurysm
5.7.3 Rebleeding
5.7.4 Critical care management
5.7.5 DCI and vasospasm

6 Recognized Establishments

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7 Major Markets Epidemiology
7.2.1 Incidence of Subarachnoid Hemorrhage (SAH) in the 7MM
7.2.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM
7.3 United States
7.3.1 Assumption and Rationale
7.3.2 Incidence of Subarachnoid Hemorrhage (SAH) in the United States
7.3.3 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
7.3.4 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
7.3.5 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
7.3.6 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
7.3.7 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
7.4 EU-5 Epidemiology
7.4.1 Assumption and rationale
7.5 Germany
7.5.1 Incidence of Subarachnoid Hemorrhage (SAH) in Germany
7.5.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the Germany
7.5.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the Germany
7.5.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
7.5.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
7.5.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
7.6 France
7.6.1 Incidence of Subarachnoid Hemorrhage (SAH) in France
7.6.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
7.6.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
7.6.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
7.6.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
7.6.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
7.7 Italy
7.7.1 Incidence of Subarachnoid Hemorrhage (SAH) in Italy
7.7.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
7.7.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
7.7.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
7.7.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
7.7.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
7.8 Spain
7.8.1 Incidence of Subarachnoid Hemorrhage (SAH) in Spain
7.8.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
7.8.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
7.8.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
7.8.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
7.8.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
7.9 United Kingdom
7.9.1 Incidence of Subarachnoid Hemorrhage (SAH) in the United Kingdom
7.9.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
7.9.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
7.9.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
7.9.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
7.9.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
7.10 Japan
7.10.1 Assumption and Rationale
7.10.2 Incidence of Subarachnoid Hemorrhage (SAH) in Japan
7.10.3 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
7.10.4 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
7.10.5 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
7.10.6 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
7.10.7 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan

8 Treatment of Aneurysmal Subarachnoid hemorrhage (aSAH)
8.1.1 Calcium channel blockers
8.1.2 Pain-relieving medications
8.1.3 Anticonvulsants
8.1.4 Surgery
8.2 Upcoming Therapies
8.3 Treatment Guidelines for SAH
8.4 Treatment of Delayed ischemic neurologic deficit (DIND) or delayed cerebral ischemia (DCI)
8.4.1 Clearance of subarachnoid spaces
8.4.2 Systemic targeting of angiographic vasospasm
8.4.3 Local delivery
8.4.4 Drugs with multidirectional effects/neuroprotection
8.4.5 Microthrombosis
8.4.6 Free radicals and inflammation
8.4.7 Induced hypertension for the treatment of vasospasm
8.4.8 Intra-Arterial Vasodilator Therapy
8.4.9 Other Endovascular Techniques
8.4.10 Cardiac output augmentation
8.4.11 Clearance of subarachnoid spaces
8.4.12 Triple H therapy
8.5 Treatment algorithm
8.6 Prevention of DCI
8.7 Conclusion

9 Unmet Needs

10 Marketed Drugs
10.1 Nymalize (nimodipine): Arbor Pharmaceuticals
10.1.1 Drug Description
10.1.2 Regulatory Milestones
10.1.3 Other Developmental Activities
10.1.4 Advantages and Disadvantages
10.1.5 Safety and Efficacy
10.1.6 Product Profile

11 Emerging Drugs
11.1 Key Cross Competition
11.2 SFX-01: Evgen Pharma
11.2.1 Product Description
11.2.2 Regulatory Milestones
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.2.5 Advantages and Disadvantages
11.2.6 Product Profile
11.3 Clazosentan: Idorsia Pharmaceuticals
11.3.1 Product Description
11.3.2 Regulatory Milestones
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.3.5 Advantages and Disadvantages
11.3.6 Product Profile
11.4 GTX-104: Grace Therapeutics
11.4.1 Product Description
11.4.2 Other Developmental Activity
11.4.3 Product Profile
11.5 EG-1962: Edge Therapeutics/PDS Biotechnology Corporation
11.5.1 Product Description
11.5.2 Regulatory Milestones
11.5.3 Clinical Development
11.5.4 Product Profile
11.6 Nicaplant (nicardipine): BIT Pharma
11.6.1 Product Description
11.6.2 Regulatory Milestones
11.6.3 Clinical Development
11.6.4 Product Profile

12 Aneurysmal Subarachnoid Hemorrhage (aSAH): 7 Major Market Analysis
12.1 Key Findings
12.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM Countries
12.1.1 Market Size by Therapies

13 7MM Market Outlook

14 United States Market Size
14.1.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
14.1.2 Market Size by Therapies

15 EU-5 Market Size
15.1 Germany
15.1.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.1.2 Market Size by Therapies
15.2 France
15.2.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.2.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
15.3 Italy
15.3.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.3.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
15.4 Spain
15.4.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.4.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
15.5 United Kingdom
15.5.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.5.2 Market Size by Therapies
15.6 Japan Market Size
15.6.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
15.6.2 Market Size by Therapies

16 Conjoint Analysis

17 Access and Reimbursement

18 Case Reports
18.1 Patient Story: Delayed Spinal Arachnoiditis Following Aneurysmal Subarachnoid Hemorrhage

19 Market Drivers

20 Market Barriers

21 Appendix

22 Capabilities

23 Disclaimer

24 About the Publisher
Note: Product cover images may vary from those shown
3 of 3
  • Arbor Pharmaceuticals
  • Evgen Pharma
  • Idorsia Pharmaceuticals
  • Grace Therapeutics
  • Edge Therapeutics/PDS Biotechnology Corporation
  • BIT Pharma
Note: Product cover images may vary from those shown
Adroll
adroll